ChemoCentryx Stock Forecast, Price & News

ChemoCentryx (NASDAQ:CCXI) Frequently Asked Questions

Is ChemoCentryx a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last year. There are currently 1 hold rating, 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ChemoCentryx stock.
View analyst ratings for ChemoCentryx or view top-rated stocks.

How has ChemoCentryx's stock price been impacted by Coronavirus (COVID-19)?

ChemoCentryx's stock was trading at $41.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CCXI stock has decreased by 21.8% and is now trading at $32.50.
View which stocks have been most impacted by COVID-19.

Are investors shorting ChemoCentryx?

ChemoCentryx saw a decrease in short interest during the month of November. As of November 30th, there was short interest totaling 4,920,000 shares, a decrease of 18.5% from the November 15th total of 6,040,000 shares. Based on an average trading volume of 4,830,000 shares, the short-interest ratio is presently 1.0 days. Currently, 8.6% of the company's stock are short sold.
View ChemoCentryx's Short Interest.

When is ChemoCentryx's next earnings date?

ChemoCentryx is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for ChemoCentryx.

How were ChemoCentryx's earnings last quarter?

ChemoCentryx, Inc. (NASDAQ:CCXI) announced its earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.32) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.45) by $0.13. The biopharmaceutical company had revenue of $17.74 million for the quarter, compared to analysts' expectations of $14.70 million. ChemoCentryx had a negative net margin of 353.41% and a negative trailing twelve-month return on equity of 34.78%. During the same quarter in the prior year, the company earned ($0.35) earnings per share.
View ChemoCentryx's earnings history.

What price target have analysts set for CCXI?

6 equities research analysts have issued 1 year price targets for ChemoCentryx's stock. Their forecasts range from $38.00 to $110.00. On average, they anticipate ChemoCentryx's stock price to reach $75.00 in the next year. This suggests a possible upside of 130.8% from the stock's current price.
View analysts' price targets for ChemoCentryx or view top-rated stocks among Wall Street analysts.

Who are ChemoCentryx's key executives?

ChemoCentryx's management team includes the following people:

• Thomas J. Schall, Chairman, President & Chief Executive Officer
• Tausif Butt, Chief Operating Officer & Executive Vice President (LinkedIn Profile)
• Susan M. Kanaya, Chief Financial Officer, Secretary & Director
• Rita I. Jain, Chief Medical Officer, Executive Director & EVP
• Sangita Ghosh, Senior Vice President-Technical Operations

What is Thomas J. Schall's approval rating as ChemoCentryx's CEO?

10 employees have rated ChemoCentryx CEO Thomas J. Schall on Glassdoor.com. Thomas J. Schall has an approval rating of 58% among ChemoCentryx's employees. This puts Thomas J. Schall in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of ChemoCentryx's key competitors?

Some companies that are related to ChemoCentryx include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Exact Sciences (EXAS), Repligen (RGEN), United Therapeutics (UTHR), Novavax (NVAX), Neurocrine Biosciences (NBIX) and Exelixis (EXEL).
View all of CCXI's competitors.

What other stocks do shareholders of ChemoCentryx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ChemoCentryx investors own include Exelixis (EXEL), Energy Transfer (ET), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Amicus Therapeutics (FOLD), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Advanced Micro Devices (AMD) and Arrowhead Pharmaceuticals (ARWR).

What is ChemoCentryx's stock symbol?

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

How do I buy shares of ChemoCentryx?

Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ChemoCentryx's stock price today?

One share of CCXI stock can currently be purchased for approximately $32.50.

How much money does ChemoCentryx make?

ChemoCentryx has a market capitalization of $2.27 billion and generates $64.89 million in revenue each year. The biopharmaceutical company earns $-55.36 million in net income (profit) each year or ($1.74) on an earnings per share basis.

How many employees does ChemoCentryx have?

ChemoCentryx employs 133 workers across the globe.

What is ChemoCentryx's official website?

The official website for ChemoCentryx is www.chemocentryx.com.

Where are ChemoCentryx's headquarters?

ChemoCentryx is headquartered at 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043.

How can I contact ChemoCentryx?

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at (650) 210-2900, via email at [email protected], or via fax at 650-210-2910.